Abstract
Scattered reports have suggested that as many as one-half of all hospital inpatients identified as COVID-positive are incidental cases who were admitted primarily for reasons other than their viral infections. To date, however, there are no systemic studies of a representative panel of hospitals based on pre-established criteria for determining whether an individual patient was in fact admitted as a result of the disease. To fill this gap, we developed a formula to estimate the fraction of incidental COVID hospitalizations that relies upon measurable, population-based parameters. We applied this approach to a longitudinal panel of 164 counties throughout the United States, covering a 4-week interval ending in the first week of January 2022. Within this panel, we estimated that COVID incidence has been rising exponentially at a rate of 9.34% per day (95% CI, 8.93-9.87). Assuming that only one-quarter of all recent Omicron infections have been reported by public authorities, we further estimated the aggregate prevalence of active SARS-CoV-2 infection during the first week of January to be 4.89%. During the same week, among 250 high-COVID-volume hospitals within our 164-county panel, an estimated 1 in 4 inpatients was COVID-positive. Among such COVID-positive hospitalized patients, 15.2% were estimated to be incidental infections. Across individual counties, the median fraction of incidental COVID hospitalizations was 13.7%, with an interquartile range of 9.5 to 18.4%. Incidental COVID infections appear to be a nontrivial fraction of all COVID-positive hospitalized patients. In the aggregate, however, the burden of patients admitted for complications of their viral infections appears to be far greater.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study relies exclusively on publicly available data that contain no individual identifiers. The source data are enumerated in the manuscript references.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Email: jeffrey{at}mit.edu
↵† This study relies exclusively on publicly available data that contain no individual identifiers. The author has no competing interests and no funding sources to declare. This article represents the sole opinion of its author and does not necessarily represent the opinions of the Massachusetts Institute of Technology, Eisner Health, or any other organization. Supporting programs and data have been posted at https://osf.io/7umje/.
Data Availability
Data and analyses are available via the Open Science Framework (OSF) at https://osf.io/7umje/
